Istradefylline comment watch save

  • TRADE NAME: Nourianz (Kyowa Kirin)
  • INDICATIONS: Indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) experiencing “off” episodes.
  • CLASS: Adenosine A2A receptor agonist
  • HALF-LIFE: approximately 83 hours
  • FDA APPROVAL DATE: 08/27/2019
  • CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
    strong CYP3A4 Inducers, strong CYP3A4 Inhibitors
  • PREGNANCY: There are no adequate data on the developmental risk associated with the use of istradefylline in pregnant women.

Use during pregnancy is not recommended. Women of childbearing potential should be advised to use contraception during treatment with istradefylline.

Because of the potential risk of exacerbating psychosis, patients with a major psychotic disorder should not be treated with istradefylline.




Please login to view the rest of this drug profile.

    DRUG REVIEW ARTICLE

    Click on the DRUG REVIEW ARTICLE tab (above) to see a review of istradefylline in the Taylor & Francis journal Expert Opinion on Drug Safety.

     

     

    (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 07/31/2023

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top